Cannabidiol and THC study for gut health and brain inflammation in HIV
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether cannabidiol (CBD) and tetrahydrocannabinol (THC) change the gut microbiome and brain-related inflammation in people with HIV. It may help researchers understand new ways to reduce inflammation, but you would need strict cannabis and CBD/THC avoidance during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 21 and 70 years old
- You can understand and sign consent for brain and health assessments
- You have used cannabis at least once in the past 5 years without serious side effects like psychosis or fainting
- In the last 2 weeks, you used little to no cannabis (none, or only once)
- You can avoid all cannabis, CBD, THC, and synthetic cannabinoids for the full 6-week study period
- For people with HIV: your virus is controlled on stable HIV medicine for at least 6 months, and your immune cells (CD4) are at least 350
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether ongoing marijuana use changes “brain inflammation” and brain cell injury in people living with HIV. It may help researchers understand potential risks or protective effects and how treatment and brain health interact.
This study looks at brain activity to understand how depression and cannabis use may be linked in young adults living with HIV. It mainly involves questionnaires, mental health screening, and brain scans, which may help researchers better understand risk factors and brain “underpinnings.”
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
This Phase 2 study looks at how THC (from cannabis) changes brain signals during working memory tasks. It uses EEG and MEG (noninvasive brain recording) to understand changes in “neural noise” and how well information moves through memory networks.
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
This early (Phase 1) study tests how an oral THC and CBD product affects the body in healthy adults who use cannabis only rarely. It may help researchers understand safety and effects before larger studies.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.